Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.



The ZERO Prostate Cancer Run/Walk is the time we come together, raising funds and sharing hope to declare one number above others: ZERO. Your participation in the ZERO Prostate Cancer Run/Walk makes a real difference in the lives of men and families fighting prostate cancer. From funding research for a test to distinguish aggressive from slowing growing disease, to providing educational and support resources to at risk men in your community, you are driving ZERO’s mission to end prostate cancer!

Find a Run/Walk near you

Visit our National Run/Walk site

Support a Participant

  • Search
  • Newsletter Signup Enews Signup
  • Donate

Shining Down

Jim Lafferty was diagnosed with stage IV prostate cancer at the young age of 35. His diagnosis followed nearly five years of urinary and erectile issues, which failed to lead to a prostate exam or PSA test in his earlier stages. Despite his diagnosis, and due to his extraordinary personality, Jim never laid down to his disease. Instead, he made his remaining years a passionate endeavor to educate men of all ages and their families about prostate cancer, treatment options, and sharing his story in every forum he could. He fought not only for himself and all affected by prostate cancer, but tirelessly for the future of his young son, Gavin. Jim lost his life to the disease in 2010 at the age of 40.

Shining Down, Inc. was founded by Jennifer Lafferty and Tamara Wyman Gardner in memory and honor of Jim. Jim’s life changing impact on others was immeasurable, and by funding targeted prostate cancer research, his family hopes to positively impact the lives of men and their families in his name.  The work of Shining Down fulfills a promise made to Jim in his final days to continue the fight for increased awareness and research funding. In partnership with ZERO, Shining Down funds research that will lead to improved diagnostic and treatment options, and someday a cure.